Umckaloabo

Umckaloabo/Drug Interactions:

  • AntibioticsAntibiotics: Based on in vitro study, umckaloabo may exert antibacterial effects against a wide range of gram-negative and gram-positive bacteria (17; 4; 12; 13; 18; 14; 19; 20). The effects of umckaloabo with antibiotics are not well understood.
  • Anticoagulants/antiplateletsAnticoagulants/antiplatelets: Based on in vitro study, umckaloabo contains coumarin, a natural anticoagulant, as one of its main constituents (4). Theoretically, concurrent use of anticoagulants or antiplatelets and umckaloabo may increase the risk of bleeding.
  • Cardiovascular agentsCardiovascular agents: Based on human case reports, umckaloabo may cause tachycardia, and theoretically may alter the effects of cardiovascular agents (16).
  • Hepatotoxic agentsHepatotoxic agents: Umckaloabo contains coumarin (4) which may cause hepatotoxicity when consumed in large amounts. Theoretically, concurrent use of hepatotoxic agents and umckaloabo may increase the risk of liver damage.
  • ImmunosuppressantsImmunosuppressants: Based on in vitro studies, umckaloabo may have immunostimulant effects (8; 21; 4; 17; 22; 23; 24). Theoretically, umckaloabo may interfere with the effects of immunosuppressants.
  • LaxativesLaxatives: Based on human study, umckaloabo may cause a laxative effect (16). Theoretically, concurrent use of umckaloabo and laxatives may cause additive effects.
  • Umckaloabo/Herb/Supplement Interactions:

  • Antibacterials Antibacterials : Based on in vitro study, umckaloabo may exert antibacterial effects (17; 4; 12; 13; 18; 14; 19; 20). The effects of umckaloabo with antibacterial agents are not well understood.
  • Anticoagulants/antiplateletsAnticoagulants/antiplatelets: Based on in vitro study, umckaloabo contains coumarin, a natural anticoagulant, as one of its main constituents (4). Theoretically, concurrent use of anticoagulants or antiplatelets and umckaloabo may increase the risk of bleeding .
  • Cardiovascular herbs and supplementsCardiovascular herbs and supplements: Based on human case reports, umckaloabo may cause tachycardia, and theoretically may alter the effects of cardiovascular agents (16).
  • Hepatotoxic agentsHepatotoxic agents: Umckaloabo contains coumarin (4), which may cause hepatotoxicity when consumed in large amounts. Theoretically, concurrent use of hepatotoxic agents and umckaloabo may increase the risk of liver damage.
  • ImmunosuppressantsImmunosuppressants: Based on in vitro studies, umckaloabo may have immunostimulant effects (8; 21; 4; 17; 22; 23; 24). Theoretically, umckaloabo may interfere with the effects of immunosuppressants.
  • LaxativesLaxatives: Based on human study, umckaloabo may cause a laxative effect (16). Theoretically, concurrent use of umckaloabo and laxatives may cause additive effects.
  • Umckaloabo/Food Interactions:

  • Insufficient evidence available.
  • Umckaloabo/Lab Interactions:

  • Bacterial culturesBacterial cultures: Based on in vitro study, umckaloabo may exert antibacterial effects against a wide range of gram-negative and gram-positive bacteria (17; 4; 12; 13; 18; 14; 19; 20).
  • Coagulation panelCoagulation panel: Based on in vitro study, umckaloabo contains coumarin, an anticoagulant, as one of its main constituents (4).
  • Heart rateHeart rate: Based on human case reports, umckaloabo may cause tachycardia (16).
  • Immune panelImmune panel: In vitro studies indicate that Pelargonium sidoides may increase immune function (8; 21; 4; 17; 22; 23).
  • Liver function testsLiver function tests: Umckaloabo contains coumarin (4), which may cause hepatotoxicity and elevated liver enzymes when consumed in large amounts.